Concord Biotech Q2 FY27 Revenue Rises 25.1% to ₹309 Crore

Concord Biotech reported consolidated revenue from operations of ₹309.07 crore for the quarter ended September 30, 2026, marking a 25.10% increase from ₹247.06 crore a year earlier. Consolidated profit after tax rose 10.32% year-on-year to ₹69.57 crore. The company disclosed the unaudited Q2 and half-year FY27 results in a filing with the BSE on October 27, 2026.

The result provides an updated view of the biopharmaceutical company's operating performance after a series of regulatory approvals and a board decision to issue bonus shares. A separate rounded market snapshot had put quarterly revenue at ₹312 crore and year-on-year growth at 26.32%. The BSE filing reports the more precise consolidated revenue figure of ₹309.07 crore, which is used in this report.

Consolidated revenue rises from the prior-year base

Revenue from operations increased by ₹62.01 crore over Q2 FY26. The comparable prior-year revenue was ₹247.06 crore, based on the filing's reported amount of ₹24,705.75 lakh. The Q2 FY27 figure was ₹30,907.02 lakh, equivalent to ₹309.07 crore after converting lakh to crore.

The increase follows demand recovery across Concord Biotech's biopharmaceutical and active pharmaceutical ingredient portfolios, according to the supplied market context. The company also operates in formulation segments, which were cited as part of its operating momentum. The filing itself reports the consolidated financial outcome but does not provide a segment-wise revenue break-up in the information available here.

Profit after tax grows at a slower pace

Consolidated profit after tax was ₹69.57 crore in Q2 FY27, compared with ₹63.06 crore in Q2 FY26. This represents an increase of ₹6.51 crore, or 10.32% year-on-year. Revenue growth therefore exceeded the reported pace of profit growth during the quarter.

The available disclosure does not specify the cost, pricing, tax or product-mix factors behind the difference between revenue and profit growth. As a result, the quarterly figures establish the movement in the top line and net profit, but do not support conclusions on margins or their drivers. Investors will have access to management's discussion during the scheduled earnings call.

Key Q2 FY27 financial figures

All absolute figures in the table are converted into crore from the BSE filing's lakh-based disclosures. The reported revenue number differs slightly from the ₹312 crore figure in the initial market snapshot because that figure is rounded and appears to draw on a separate presentation of quarterly data.

Half-year results were also approved

The board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Consolidated revenue from operations for the first half of FY27 was reported at ₹566.56 crore, converted from ₹56,655.92 lakh.

No comparable first-half FY26 revenue or first-half profit figure was included in the provided material. It is therefore not possible to calculate a half-year growth rate from the available data. The board meeting also considered the statutory auditors' limited review report on the unaudited standalone and consolidated results.

USFDA approvals form part of recent updates

Concord Biotech received USFDA approval for Tofacitinib tablets in August 2026. That followed a June 2026 USFDA approval for Mycophenolate Mofetil oral suspension. The supplied context identifies these approvals as recent product developments relevant to the company's formulation portfolio.

These regulatory clearances came before the September quarter results. However, the information provided does not quantify their contribution to Q2 revenue, sales volumes or profit. Their presence in the company's recent developments is relevant because formulation approvals can expand the set of products a company is permitted to market in the United States.

Board fixes November 4 bonus-share record date

In September 2026, Concord Biotech's board approved a 1:1 bonus share issue. The board has fixed Wednesday, November 4, 2026, as the record date for determining eligible shareholders for the bonus equity shares.

A 1:1 bonus issue means one additional equity share is issued for every one share held by eligible investors on the record date, subject to the terms of the approved issue. It changes the number of shares held by eligible shareholders but does not by itself represent operating revenue or profit. The record-date announcement was included alongside the quarterly financial results.

Committee changes were also disclosed

The company said its Audit Committee, Nomination and Remuneration Committee, Risk Management Committee and Corporate Social Responsibility Committee had been reconstituted. The supplied information does not list the revised composition or the reasons for the changes.

Committee reconstitution is a governance disclosure separate from the quarterly financial performance. It was reported with the results and bonus-share record-date information. The board meeting was scheduled for October 27, 2026 to consider the Q2 and H1 FY27 numbers.

Earnings call scheduled for October 28

Concord Biotech has scheduled an earnings call for October 28, 2026, at 3:30 PM IST. Management is expected to discuss the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Analysts and investors were invited to join through dial-in arrangements and a registration link.

The call is the next confirmed event linked to the results announcement. It may provide further detail on quarterly operations, product approvals and near-term business conditions. The provided material does not include management guidance or a formal outlook.

What the quarterly update means for investors

The central financial takeaway is that Concord Biotech recorded a double-digit increase in both consolidated revenue and profit after tax in Q2 FY27. Revenue rose 25.10% while profit after tax rose 10.32%, using the precise figures disclosed to the BSE. The company also reported first-half revenue of ₹566.56 crore and confirmed the November 4 record date for its approved 1:1 bonus issue.

For investors, the relevant near-term dates are the October 28 earnings call and the November 4 bonus-share record date. Further operating detail, including any explanation of the quarterly profitability trend, will depend on information shared by the company in its earnings discussion or subsequent disclosures.